- Conditions
- Alzheimer's Disease
- Interventions
- LY2886721, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2017–2040
of 6,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Childhood Cancer
- Interventions
- Mila Blooms
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Schizophrenia
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more
- Conditions
- Resilience, Stress
- Interventions
- MBAT with proctored practice, MBAT with non-proctored practice
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Fort Drum, New York
- Conditions
- Neoadjuvant Therapy in Rectal Cancer
- Interventions
- E7046, Long Course Chemoradiotherapy (LCRT), Short Course Radiotherapy (SCRT), capecitabine, folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
- Drug · Radiation
- Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Postsurgical Pain Management
- Interventions
- TLC590, Ropivacaine
- Drug
- Lead sponsor
- TLC Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • Houston, Texas
- Conditions
- Opioid Use
- Interventions
- Acetaminophen, Fentanyl, Propofol
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 56 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Multiple Myeloma
- Interventions
- CLN-619
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Tegavivint, Lenvatinib, Cabozantinib
- Drug
- Lead sponsor
- Iterion Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Duarte, California • Miami, Florida • Chicago, Illinois + 4 more
- Conditions
- Healthy
- Interventions
- Varegacestat Reference Formulation, Varegacestat Test Formulation A, Varegacestat Test Formulation B, Varegacestat Test Formulation C
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Cystic Fibrosis
- Interventions
- VX-272, Placebo, Tezacaftor, Deutivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
- Interventions
- Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
- Drug · Procedure · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 5 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Myelodysplastic Syndromes
- Interventions
- ARRY-614, p38/Tie2 inhibitor; oral
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Atlanta, Georgia • Houston, Texas
- Conditions
- Opioid Dependence, Acute Opioid Withdrawal Syndrome
- Interventions
- Lofexidine HCl, Placebo, Open Label Lofexidine HCL
- Drug
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 18
- States / cities
- Clovis, California • Escondido, California • San Diego, California + 15 more
- Conditions
- Lung Cancer, Early Lung Cancer Detection
- Interventions
- DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test, Low-Does CT Scan
- Diagnostic Test
- Lead sponsor
- Jill Kolesar
- Other
- Eligibility
- 50 Years to 77 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Waterloo, Iowa
- Conditions
- Parapsoriasis, Healthy Volunteers
- Interventions
- CC-90005, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- Traction Device
- Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Well-being at Work, Burnout
- Interventions
- Ambient AI Scribe
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sepsis
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Interventions
- GEN3014, Daratumumab
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Cleveland, Ohio • Milwaukee, Wisconsin
- Conditions
- Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
- Interventions
- Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy
- Interventions
- BT-600, BT-600 Placebo
- Combination Product
- Lead sponsor
- Biora Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 4
- States / cities
- Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more